...for Hangzhou SciwindHangzhou Sciwind Biosciences Co. Ltd. closed a $37 million series B round, with LYFE Capital...

...Price; affiliates of BlackRock; Perceptive Advisors; and LYFE Capital.Participants...

...E round included Hudson Bay Capital Management, RA Capital, Hangzhou Tigermed Consulting Co. Ltd (SZSE:300347) and Lyfe Capital.TARGETSHER2...

...population scale.” Mao Mao, SeekIn The market potential for pre-symptomatic screening looms especially large in China. Lyfe Capital’s...
...projects China’s early cancer screening market will be $25-30 billion in the next ten years. Lyfe Capital...
...Johnson & Johnson (NYSE:JNJ) to track over 3,000 patients with pulmonary nodules identified by CT scans. Lyfe Capital’s...

...fellow existing Chinese investors Yuanming Capital, Lilly Asia Ventures, Matrix Partners China, 3E Bioventures and LYFE Capital...

...in a couple years. Existing investors Sequoia Capital China, VI Ventures, Legend Star Capital and LYFE Capital...

...$29.5 million) in a series A round. GIC led Burning Rock’s financing, with participation by Lyfe Capital...

...$29.5 million) in a series A round. GIC led Burning Rock’s financing, with participation by Lyfe Capital...

...Fund and Lilly Asia Ventures led the round, with participation from fellow new Chinese investors Lyfe Capital...
...of operations. “China demonstrates a strong market potential for Ansun in the future.” James Zhao, Lyfe Capital...
...led by Sequoia China and Lyfe. Jennie Walters, Staff Writer Fludase, ParaDase (DAS181) Ansun BioPharma Inc. FOG Pharmaceuticals Inc. HiFiBiO Therapeutics Lyfe Capital...

...series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital...